IMAB362: Phase II data

Top-line data from the open-label, European Phase II FAST trial in 161 patients with CLND18.2-positive advanced or recurrent gastric or gastroesophageal junction cancer who have not received previous chemotherapy showed

Read the full 300 word article

User Sign In